Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
11.30
-0.45 (-3.83%)
At close: Oct 30, 2026, 4:00 PM EDT
11.66
+0.36 (3.19%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Vir Biotechnology Employees
Vir Biotechnology had 367 employees as of December 31, 2025. The number of employees decreased by 41 or 10.05% compared to the previous year. That makes Vir Biotechnology the 22,461st largest employer in the world and 2,920th in the United States.
Employees
367
Change (1Y)
-41
Growth (1Y)
-10.05%
Revenue / Employee
$826,232
Profits / Employee
-$685,774
Market Cap
1.91B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 367 | -41 | -10.05% |
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Sep 30, 2021 | 395 | 98 | 33.00% |
| Jun 30, 2021 | 367 | 114 | 45.06% |
| Mar 31, 2021 | 340 | 103 | 43.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Immunome | 247 |
| Zymeworks | 231 |
| Lakefront Biotherapeutics NV | 196 |
| Absci | 140 |
| Trevi Therapeutics | 34 |
| SELLAS Life Sciences Group | 13 |
VIR News
- 2 days ago - Vir Biotechnology appoints Suzanne Topalian to board of directors - TheFly
- 2 days ago - Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors - Business Wire
- 9 days ago - Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results - Business Wire
- 16 days ago - Vir Biotechnology enters collaboration, license agreement with Gilead - TheFly
- 16 days ago - Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Business Wire
- 22 days ago - Vir Biotechnology announces U.S. FDA granted FTD to VIR-5500 - TheFly
- 22 days ago - Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer - Business Wire
- 23 days ago - Vir Biotechnology price target raised to $22 from $20 at H.C. Wainwright - TheFly